Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: A retrospective case series

Expert Review of Neurotherapeutics

Volumn 12, Issue 8, 2012, Pages 929-936

  Chamberlain, Marc C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

bevacizumab; bevacizumab and a cytotoxic chemotherapy; bevacizumab refractory; recurrent glioblastoma

Indexed keywords

ANTIEMETIC AGENT; BENDAMUSTINE; BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; ERLOTINIB; ETOPOSIDE; IRINOTECAN; NITROSOUREA; RILOTUMUMAB; TEMOZOLOMIDE; TEMSIROLIMUS; VERUBULIN;

ANEMIA; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CONSTIPATION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HUMAN; HYPERTENSION; INFECTION; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIATION DOSE; REOPERATION; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND DEHISCENCE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 84866709316     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.84     Document Type: Review

References (41)

1. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10), 779-787 (2008).
2. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
3. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
4. Iwamoto FM, Fine HA. Bevacizumab for malignant gliomas. Arch. Neurol. 67(3), 285-288 (2010).
5. Brem SS, Bierman PJ, Brem H et al.; National Comprehensive Cancer Network. Central nervous system cancers. J. Natl. Compr. Canc. Netw. 9(4), 352-400 (2011).
6. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 116(17), 3988-3999 (2010).
7. Attenello FJ, Mukherjee D, Datoo G et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann. Surg. Oncol. 15(10), 2887-2893 (2008).
8. Perry JR, Blanger K, Mason WP et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 28(12), 2051-2057 (2010).
9. Combs SE, Bischof M, Welzel T et al. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J. Neurooncol. 89(2), 205-210 (2008).
10. Fogh SE, Andrews DW, Glass J et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J. Clin. Oncol. 28(18), 3048-3053 (2010).
11. Park JK, Hodges T, Arko L et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J. Clin. Oncol. 28(24), 3838-3843 (2010).
12. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168-1174 (2010).
13. Batchelor TT, Mulholland P, Neyns B et al. The efficacy of cediranib as monotherapy and in combination with lomustine alone in patients with recurrent glioblastoma: a phase III randomized study. Neuro. Oncol. 12(Suppl. 4), iv69-iv78 (2010).
14. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neurooncology 12(12), 1300-1310 (2010).
15. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
16. Maron R, Vredengurgh JJ, Desjardins A et al. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. 26(15s), 2074 (2008).
17. Wen P, Macdonald DR, Reardon DA et al. Proposal for an updated response assessment criteria for high-grade gliomas: radiology assessment for Neuro-Oncology Working Group. J. Clin. Oncol. 28, 1963-1972 (2009).
18. Quant EC, Norden AD, Drappatz J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-oncology 11(5), 550-555 (2009).
19. Chamberlain MC, Johnston SK. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J. Neurooncol. 96(2), 259-269 (2010).
20. Torcuator RG, Thind R, Patel M et al. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J. Neurooncol. 97(3), 401-407 (2010).
21. Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72(14), 1217-1222 (2009).
22. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8), 1258-1260 (2006).
23. Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br. J. Cancer 101(12), 1986-1994 (2009).
24. Gaziel TB, Sorensen M, Hasselbalch B, Poulsen HS, Lassen U. Phase II study of bevacizumab and temsirolimus in patients with progressive glioblastoma multiforme after prior bevacizumab treatment. Neuro-oncology 12(Suppl. 4), iv36-iv57 (2010).
25. Lu-Emerson C, Norden AD, Drappatz J et al. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J. Neurooncol. 104(1), 287-291 (2011).
26. Grimm S, Phuphanich S, Recht LD et al. Phase 2 study of Azixa (MPC-6827) for the treatment of patients with recurrent glioblastoma multiforme having previously failed bevacizumab. Neuro-oncology 12 (iv1-iv136), iv51 (2010).
27. Chamberlain MC, Graham C, Mrugala M, Johnston S. Bendamustine for recurrent glioblastoma. J. Neurooncol. 105(3), 523-530 (2011).
28. Wen P, Prados M, Chamberlain M et al. A Phase 2 study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2 and RET, in patients with relapsed glioblastoma (GB): determination of the optimal regimen. J. Clin. Oncol. 28(Suppl. 15), 181s (2010).
29. Wen PY, Schiff D, Cloughesy TF et al. A Phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-oncology 13(4), 437-446 (2011).
30. Reardon DA, Desjardins A, Peters K et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J. Neurooncol. 103(2), 371-379 (2011).
31. Reardon DA, Desjardins A, Peters KB et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117(23), 5351-5358 (2011).
32. Iwamoto FM, Abrey LE, Beal K et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15), 1200-1206 (2009).
33. Cloughesy T, Vredenburgh JJ, Day B; the BRAIN Investigators. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J. Clin. Oncol. 28(Suppl. 15), 181s (2010).
34. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592-603 (2008).
35. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8(8), 618-631 (2008).
36. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15(3), 167-170 (2009).
37. Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039-2049 (2008).
38. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438(7070), 932-936 (2005).
39. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev. Anticancer Ther. 7(11), 1537-1560 (2007).
40. Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev. Neurother. 9(4), 519-534 (2009).
41. Desjardins A, Reardon DA, Coan A et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118(5), 1302-1312 (2012).